Comparative Pharmacology
Head-to-head clinical analysis: SELENIUM SULFIDE versus TIOCONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SELENIUM SULFIDE versus TIOCONAZOLE.
SELENIUM SULFIDE vs TIOCONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selenium sulfide is an antifungal and cytostatic agent. It reduces sebum production and inhibits the growth of Malassezia species by interfering with fungal lipid metabolism and cell wall synthesis. The exact molecular mechanism is not fully elucidated.
Inhibition of fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Topical: 2.5% lotion or shampoo applied to affected area once daily for 7 days; 1% shampoo used once or twice weekly for maintenance.
Topical: Apply 1% cream, lotion, or solution to affected area twice daily for 2-4 weeks. Vaginal: Insert 1 applicatorful of 6.5% ointment intravaginally at bedtime as a single dose.
None Documented
None Documented
Clinical Note
moderateTioconazole + Tranilast
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Tranilast."
Clinical Note
moderateTioconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Tolfenamic acid."
Clinical Note
moderateTioconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Nimesulide."
Clinical Note
moderateTioconazole + Risedronic acid
Not established; due to negligible systemic absorption, a terminal half-life is not clinically relevant. If absorbed, selenium has a long biological half-life of approximately 65–115 days due to incorporation into selenoproteins.
Terminal elimination half-life is approximately 24–30 hours after topical application, reflecting slow systemic clearance of absorbed fraction.
Selenium sulfide is minimally absorbed after topical application. The small absorbed fraction is excreted renally as selenite or selenate, with fecal excretion of unabsorbed drug accounting for >90% of the dose.
Primarily fecal (minimally absorbed; <5% absorbed dose excreted renally as metabolites); topically applied tioconazole is largely unabsorbed.
Category A/B
Category A/B
Antifungal / Antiseborrheic
Antifungal
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Risedronic acid."